ArticleBiomedical reports2025
Silencing of AEBP1 inhibits proliferation and promotes apoptosis via the AKT signaling pathway in osteosarcoma.
Article in Biomedical reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pan-Cancer Analysis Reveals AEBP1-Collagen Co-Expression and Its Potential Role in CAF-Mediated Tumor Stiffness.International journal of molecular sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adipocyte enhancer-binding protein 1 (AEBP1) has emerged as a novel regulator in the tumorigenic progression of various cancers. Despite its significance, the expression and functions of AEBP1 in osteosarcoma (OS) remain largely unexplored. The GEO database was used to screen for novel targets of osteosarcoma and AEBP1 was focused on since its expression and functions in OS remain to be thoroughly elucidated. Thus, the aim of the present study was to investigate the potential biological functions of AEBP1 in OS. UALCAN and CCLE databases were then used to analyze the expression levels of AEBP1. By employing siRNA, AEBP1 was silenced in human OS cells and the expression of AEBP1 at the mRNA and protein levels was assessed through reverse transcription-quantitave PCR and western blot analysis, respectively. Subsequently, the effects of AEBP1 silencing on the proliferation and apoptosis of human OS cell lines were investigated using MTT, 5-ethynyl-2'-deoxyuridine, clone formation, flow cytometry and TUNEL assays. The results revealed that silencing of AEBP1 inhibited OS cell proliferation, promoted apoptosis, and induced G
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.